Suppr超能文献

日本 88 例原发性免疫缺陷患者非亲缘脐带血移植的结果。

Outcome of unrelated umbilical cord blood transplantation in 88 patients with primary immunodeficiency in Japan.

机构信息

Department of Paediatrics and Developmental Biology, Tokyo Medical and Dental University Graduate School of Medical and Dental Sciences, Tokyo, Japan.

出版信息

Br J Haematol. 2011 Aug;154(3):363-72. doi: 10.1111/j.1365-2141.2011.08735.x. Epub 2011 May 14.

Abstract

We report the results of umbilical cord blood transplantation (UCBT) performed in 88 patients with primary immunodeficiency (PID) between 1998 and 2008 in Japan; severe combined immunodeficiency (SCID, n = 40), Wiskott-Aldrich syndrome (WAS, n = 23), chronic granulomatous disease (n = 7), severe congenital neutropaenia (SCN, n = 5) and other immunodeficiencies (n = 13). Five-year overall survival (5-year OS) for all patients was 69% [95% confidence interval (CI), 57-78%], and was 71% and 82% for SCID and WAS, respectively. The main cause of death before day 100 was infection (17/19), while that after day 100 was graft-versus-host disease (GVHD) (5/7). Using multivariate analyses, pre-transplant infection, no conditioning, ≥ 2 human leucocyte antigen (HLA) mismatches or diagnosis other than SCID, SCN or WAS were all associated with poor prognosis. Reduced-intensity conditioning was associated with decreased overall mortality compared with myeloablative therapy. The cumulative incidence of grade 2-4 acute GVHD at day 100 was 28% (95% CI, 19-38%), and that of chronic GVHD at day 180 was 13% (95% CI, 7-23%). We conclude that UCBT should be considered for PID patients without an HLA-matched sibling. The control of pre-transplant infection and selection of HLA-matched donors will lead to a better outcome.

摘要

我们报告了 1998 年至 2008 年间在日本进行的 88 例原发性免疫缺陷(PID)患者脐带血移植(UCBT)的结果;严重联合免疫缺陷(SCID,n=40)、Wiskott-Aldrich 综合征(WAS,n=23)、慢性肉芽肿病(n=7)、严重先天性中性粒细胞减少症(SCN,n=5)和其他免疫缺陷(n=13)。所有患者的 5 年总生存率(5 年 OS)为 69%[95%置信区间(CI),57-78%],SCID 和 WAS 分别为 71%和 82%。100 天前死亡的主要原因是感染(19/19),100 天后死亡的原因是移植物抗宿主病(GVHD)(5/7)。使用多变量分析,移植前感染、无预处理、≥2 个人类白细胞抗原(HLA)错配或诊断为 SCID、SCN 或 WAS 以外的疾病均与预后不良相关。与清髓性治疗相比,减强度预处理与总死亡率降低相关。100 天时 2-4 级急性 GVHD 的累积发生率为 28%(95%CI,19-38%),180 天时慢性 GVHD 的累积发生率为 13%(95%CI,7-23%)。我们得出结论,对于没有 HLA 匹配同胞的 PID 患者,应考虑 UCBT。移植前感染的控制和 HLA 匹配供体的选择将导致更好的结果。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验